+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetic Retinopathy - Pipeline Insight, 2021

  • ID: 4989160
  • Clinical Trials
  • July 2021
  • Region: Global
  • 60 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • Aerie Pharmaceuticals
  • Ascentage Pharma
  • Emerald Bioscience, Inc.
  • Hengenix Biotech Inc
  • MIRAE CELL BIO
  • Ocuphire Pharma, Inc.
This Diabetic retinopathy - Pipeline Insight, 2021 provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Diabetic retinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Diabetic retinopathy Understanding


Diabetic retinopathy: Overview


Diabetic retinopathy is a serious sight-threatening complication of diabetes. Diabetes interferes with the body's ability to use and store sugar (glucose). The disease is characterized by too much sugar in the blood, which can cause damage throughout the body, including the eyes. Over time, diabetes damages small blood vessels throughout the body, including the retina. Diabetic retinopathy occurs when these tiny blood vessels leak blood and other fluids. This causes the retinal tissue to swell, resulting in cloudy or blurred vision. Diabetic retinopathy usually affects both eyes. The longer a person has diabetes, the more likely they will develop diabetic retinopathy. If left untreated, diabetic retinopathy can cause blindness. When people with diabetes experience long periods of high blood sugar, fluid can accumulate in the lens inside the eye that controls focusing. This changes the curvature of the lens, leading to changes in vision. However, once blood sugar levels are controlled, usually the lens will return to its original shape and vision improves. Patients with diabetes who can better control their blood sugar levels will slow the onset and progression of diabetic retinopathy.

Diabetic retinopathy - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic retinopathy pipeline landscape is provided which includes the disease overview and Diabetic retinopathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic retinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic retinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic retinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic retinopathy.

Diabetic retinopathy Emerging Drugs Chapters


This segment of the Diabetic retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic retinopathy Emerging Drugs


Brolucizumab: Novartis

Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) and the most clinically advanced, humanized single-chain antibody fragment to reach this stage of development. Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation and drug delivery characteristics. The proprietary innovative structure results in a small molecule (26 kDa) with potent inhibition of, and high affinity to, all VEGF-A isoforms. In preclinical studies, brolucizumab inhibited activation of VEGF receptors through prevention of the ligand-receptor interaction. Increased signaling through the VEGF pathway is associated with pathologic ocular angiogenesis and retinal edema. Inhibition of the VEGF pathway has been shown to inhibit the growth of neovascular lesions, resolve retinal edema and improve vision in patients with chorioretinal vascular diseases. Currently, it is in Phase III stage of development to treat diabetic retinopathy.

RGX 314: Regenxbio Inc.

RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for formation of new leaky blood vessels and retinal fluid accumulation. Currently, it is in Phase II stage of development to treat diabetic retinopathy.

Diabetic retinopathy: Therapeutic Assessment


This segment of the report provides insights about the different Diabetic retinopathy drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Diabetic retinopathy


There are approx. 50+ key companies which are developing the therapies for Diabetic retinopathy. The companies which have their Diabetic retinopathy drug candidates in the most advanced stage, i.e. phase III include, Novartis.

Phases


This report covers around 50+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Diabetic retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic retinopathy: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic retinopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic retinopathy drugs.

Diabetic retinopathy Report Insights

  • Diabetic retinopathy Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Diabetic retinopathy Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Diabetic retinopathy drugs?
  • How many Diabetic retinopathy drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic retinopathy?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic retinopathy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Diabetic retinopathy and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Novartis
  • Regenxbio Inc.
  • Boehringer Ingelheim
  • Bayer
  • RemeGen Co., Ltd.
  • Kubota Vision
  • Hoffmann-La Roche
  • Allegro Ophthalmics
  • MingSight Pharmaceuticals
  • Ocuphire Pharma, Inc.
  • Adverum Biotechnologies, Inc.
  • Applied Therapeutics
  • OcuNexus Therapeutics
  • Alcon
  • Aerpio Pharmaceuticals
  • EyeGene
  • Aerie Pharmaceuticals
  • OccuRx
  • NovaGo Therapeutics
  • HanAll Biopharma
  • Ascentage Pharma
  • AptaBio
  • BONAC corporation
  • CCRP Therapeutics
  • Curacle Co Ltd
  • Emerald Bioscience, Inc.
  • EnnovaBio
  • Everglades Biopharma
  • Excitant Therapeutics, LLC
  • Foresee Pharmaceuticals Co., Ltd.
  • Glycadia
  • Hengenix Biotech Inc
  • Kubota Vision Inc.
  • LUYE PHARMA
  • MIRAE CELL BIO
  • Novelty Nobility Inc
  • Noveome Biotherapeutics, Inc.
  • OliPass Corporation
  • Palatin Technologies Inc
  • PharmAbcine Inc
  • PYC Therapeutics
  • Retinset SL
  • RIBOMIC

Key Products

  • Brolucizumab
  • RGX 314
  • BI 764524
  • Runcaciguat
  • RC28-E
  • emixustat hydrochloride
  • RG7774
  • Luminate
  • MS-553
  • APX3330
  • ADVM-022
  • AT 003
  • HCB 1019
  • Nepafenac
  • Razuprotafib
  • EGT 022
  • OCX-063
  • NG 004
  • HL 190
  • UBX 1967
  • APX-1004
  • BNC-1601
  • CU06
  • FP-008
  • GLY 230
  • HLX04
  • Emixustat HCI
  • LY09004
  • NN2101
  • PMC-403
  • PYC-001
  • BSL01
  • RBM-008


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aerie Pharmaceuticals
  • Ascentage Pharma
  • Emerald Bioscience, Inc.
  • Hengenix Biotech Inc
  • MIRAE CELL BIO
  • Ocuphire Pharma, Inc.
Introduction

Executive Summary

Diabetic retinopathy: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
  • Comparative Analysis
Brolucizumab: Novartis
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
RGX 314: Regenxbio Inc.
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
LY09004: Luye Pharma
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
PYC-001: PYC Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Diabetic retinopathy Key Companies

Diabetic retinopathy Key Products

Diabetic retinopathy- Unmet Needs

Diabetic retinopathy- Market Drivers and Barriers

Diabetic retinopathy- Future Perspectives and Conclusion

Diabetic retinopathy Analyst Views

Diabetic retinopathy Key Companies

Appendix

List of Tables
Table 1 Total Products for Diabetic retinopathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Diabetic retinopathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Adverum Biotechnologies, Inc.
  • Aerie Pharmaceuticals
  • Aerpio Pharmaceuticals
  • Alcon
  • Allegro Ophthalmics
  • Applied Therapeutics
  • AptaBio
  • Ascentage Pharma
  • Bayer
  • Boehringer Ingelheim
  • BONAC corporation
  • CCRP Therapeutics
  • Curacle Co Ltd
  • Emerald Bioscience, Inc.
  • EnnovaBio
  • Everglades Biopharma
  • Excitant Therapeutics, LLC
  • EyeGene
  • Foresee Pharmaceuticals Co., Ltd.
  • Glycadia
  • HanAll Biopharma
  • Hengenix Biotech Inc
  • Hoffmann-La Roche
  • Kubota Vision
  • Kubota Vision Inc.
  • LUYE PHARMA
  • MingSight Pharmaceuticals
  • MIRAE CELL BIO
  • NovaGo Therapeutics
  • Novartis
  • Novelty Nobility Inc
  • Noveome Biotherapeutics, Inc.
  • OccuRx
  • OcuNexus Therapeutics
  • Ocuphire Pharma, Inc.
  • OliPass Corporation
  • Palatin Technologies Inc
  • PharmAbcine Inc
  • PYC Therapeutics
  • Regenxbio Inc.
  • RemeGen Co., Ltd.
  • Retinset SL
  • RIBOMIC
Note: Product cover images may vary from those shown
Adroll
adroll